Bile

Eisai Launchs Bile Acid Transporter Inhibitor Goofice in Thailand

Monday, July 19, 2021 - 1:03am

TOKYO, July 19, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced that its Thailand subsidiary Eisai (Thailand) Marketing Co., Ltd. has launched the bile acid transporter inhibitor Goofice (generic name: elobixibat hydrate) in Thailand.

Key Points: 
  • TOKYO, July 19, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced that its Thailand subsidiary Eisai (Thailand) Marketing Co., Ltd. has launched the bile acid transporter inhibitor Goofice (generic name: elobixibat hydrate) in Thailand.
  • Goofice inhibits the bile acid transporter that regulates reabsorption of bile acids thereby increasing the flow of bile acids to the colon.
  • In Asia (Thailand, Indonesia, Philippines, Malaysia, and Singapore), Eisai is responsible for the commercialization and marketing of this product under a contract with EA Pharma.
  • Eisai will continue to make a further contribution to improve QOL for patients with chronic constipation in Thailand and other Asian countries, through maximization of the product value of Goofice.

Albireo to Present at the William Blair Biotech Focus Conference 2021

Thursday, July 8, 2021 - 1:30pm

BOSTON, July 08, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced thatRon Cooper, President and Chief Executive Officer, will present at the William Blair Biotech Focus Conference on Thursday, July 15, at11:00 a.m. EDT.

Key Points: 
  • BOSTON, July 08, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced thatRon Cooper, President and Chief Executive Officer, will present at the William Blair Biotech Focus Conference on Thursday, July 15, at11:00 a.m. EDT.
  • To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time.
  • For PFIC, the FDA recently granted Priority Review and set a PDUFA goal date of July 20, 2021.
  • The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.

FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (Devimistat) for Treatment of Biliary Cancer

Tuesday, June 29, 2021 - 4:00pm

CRANBURY, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (Rafael or the Company), a leader in the growing field of cancer metabolism-based therapeutics, announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for CPI-613 (devimistat) for the treatment of biliary cancer.

Key Points: 
  • CRANBURY, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (Rafael or the Company), a leader in the growing field of cancer metabolism-based therapeutics, announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for CPI-613 (devimistat) for the treatment of biliary cancer.
  • Biliary cancer appears when cancer cells form in the bile ducts or gallbladder, an essential aspect of the gastrointestinal system.
  • The orphan drug designation for devimistat showcases the importance of discovering these new treatment options.
  • Devimistat has been granted orphan drug status by the FDA for the treatment of pancreatic cancer, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), Burkitts lymphoma, peripheral T-cell lymphomas, and soft tissue sarcoma, and now, biliary cancer.

Albireo to Present at Piper Sandler’s Virtual EASL Takeaway Day

Thursday, June 24, 2021 - 1:00pm

BOSTON, June 24, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced thatRon Cooper, President and Chief Executive Officer, will present as part of a fireside chat at Piper Sandlers Virtual EASL Takeaway Day on Monday, June 28, at10:00 a.m. EDT.

Key Points: 
  • BOSTON, June 24, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced thatRon Cooper, President and Chief Executive Officer, will present as part of a fireside chat at Piper Sandlers Virtual EASL Takeaway Day on Monday, June 28, at10:00 a.m. EDT.
  • Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases.
  • Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden.
  • The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.

Global Cholangiocarcinoma Market (2021 to 2028) - Featuring Incyte, QED Therapeutics and RenovoRx Among Others - ResearchAndMarkets.com

Thursday, May 27, 2021 - 12:13pm

Cholangiocarcinoma is a form of cancer in which epithelial cells are mutated, which means the cells show characters of epithelial differentiation in the bile duct.

Key Points: 
  • Cholangiocarcinoma is a form of cancer in which epithelial cells are mutated, which means the cells show characters of epithelial differentiation in the bile duct.
  • The bile duct carries a fluid called bile, which is secreted in the liver and stored in the gall bladder.
  • There are two types of bile duct cancer intrahepatic bile duct cancer and extrahepatic bile duct cancer.
  • The collaboration intends to co-develop and commercialize Infigratinib, an oral FGFR1-3 selective inhibitor, for patients dealing with cholangiocarcinoma (bile duct cancer).

Vivet Therapeutics Announces Multiple Projects Update, Including New VTX-803 Preclinical data To Be Presented At 2021 American Society Of Gene And Cell Therapy Annual Meeting

Monday, May 10, 2021 - 3:00pm

In people with PFIC, liver cells are less able to secrete bile or essential components into the bile.

Key Points: 
  • In people with PFIC, liver cells are less able to secrete bile or essential components into the bile.
  • The disease is estimated to affect one in every 50,000 to 100,000 births in the United States and Europe.
  • Six types of PFIC have been genetically identified, all of which are similarly characterized by impaired bile flow and progressive liver disease.
  • In PFIC3, cholestasis results from the toxicity of bile in which detergent bile salts are not inactivated by phospholipids, leading to bile canaliculi and biliary epithelium injuries.\n'

Albireo to Participate in the Needham 20th Annual Virtual Healthcare Conference

Tuesday, April 6, 2021 - 1:30pm

BOSTON, April 06, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced participation in the upcoming Needham 20th Annual Healthcare Conference on April 12-15.

Key Points: 
  • BOSTON, April 06, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced participation in the upcoming Needham 20th Annual Healthcare Conference on April 12-15.
  • Albireo executives taking part will include Ron Cooper, President and Chief Executive Officer and Simon Harford, Chief Financial Officer.
  • The team will participate in a fireside chat on April 13 at 9:30 a.m.
  • ET, which will be available on-demand on the Albireo Media & Investors page at ir.albireopharma.com , as well as hosting meeting with investors throughout the conference.

Albireo Reports Q4 and Year-End 2020 Financial Results and Business Update

Thursday, February 25, 2021 - 1:00pm

ET

Key Points: 
  • ET
    BOSTON, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare pediatric liver disease company developing novel bile acid modulators, today provided a business update and reported financial results for the fourth quarter and year endedDecember 31, 2020.
  • Under the agreement, Medison will be responsible for approval and commercialization in Israel in close alignment and with oversight from Albireo.
  • TheBoston Business Journalnamed Albireo one of the 2020 Best Places to Work inMassachusetts for the second consecutive year.
  • As a result of risks and uncertainties that Albireo faces, the results or events indicated by any forward-looking statement may not occur.

United States Biliary Cancer Market and Competitive Landscape Report 2021 - ResearchAndMarkets.com

Friday, February 12, 2021 - 3:46pm

The "US Biliary Cancer Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Biliary Cancer Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • US Biliary Cancer Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Biliary Cancer pipeline products, Biliary Cancer epidemiology, Biliary Cancer market valuations and forecast, Biliary Cancer drugs sales and competitive landscape in the US.
  • Biliary Cancer pipeline: Find out the products in clinical trials for the treatment of Biliary Cancer by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Biliary Cancer drugs: Identify key products marketed and prescribed for Biliary Cancer in the US, including trade name, molecule name, and company
    Biliary Cancer market valuations: Find out the market size for Biliary Cancer drugs in 2019 in the US.
  • Find out how the market advanced from 2017 and forecast to 2026
    Biliary Cancer drugs market share: Find out the market shares for key Biliary Cancer drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Biliary Cancer products

Mirum Pharmaceuticals Announces Data Presented During AASLD Highlighting Durable Improvements in Pruritus and Quality of Life in Children with Alagille Syndrome Treated with Maralixibat

Sunday, November 15, 2020 - 11:00pm

Maralixibat, an apical sodium bile acid transporter (ASBT) inhibitor, has previously been shown to interrupt the enterohepatic circulation of bile acids, reducing pruritus .

Key Points: 
  • Maralixibat, an apical sodium bile acid transporter (ASBT) inhibitor, has previously been shown to interrupt the enterohepatic circulation of bile acids, reducing pruritus .
  • Maralixibat treatment improved quality of life and led to improved growth parameters.
  • To view the presentation and the complete data, please visit the AASLD section within the Events page on Mirums website.
  • Children receiving maralixibat in the studies also demonstrated improvements in biomarkers of disease, including reductions in cholesterol and bile acid levels.